OTCMKTS:INCPF InnoCare Pharma (INCPF) Stock Price, News & Analysis $1.60 0.00 (0.00%) As of 10/14/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About InnoCare Pharma Stock (OTCMKTS:INCPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InnoCare Pharma alerts:Sign Up Key Stats Today's Range$1.60▼$1.6050-Day Range$1.55▼$1.8552-Week Range$1.60▼$1.85VolumeN/AAverage Volume550 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview InnoCare Pharma Limited is a biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for cancer and autoimmune diseases. The company conducts research in areas including targeted therapies, immuno-oncology and treatments designed to address significant unmet medical needs. Its primary commercial product is orelabrutinib, a highly selective Bruton's tyrosine kinase inhibitor marketed in China for certain B-cell malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma. InnoCare also maintains a pipeline of investigational therapies, including candidates aimed at autoimmune disorders, hematologic cancers and solid tumors. Founded in 2015 and headquartered in Beijing, China, InnoCare develops medicines for the Chinese market while pursuing international clinical development and commercialization opportunities. The company was co-founded by Dr. Jasmine Cui, who has served as its chairwoman and chief executive officer. InnoCare is listed in Hong Kong, and its shares also trade over the counter in the United States under the symbol INCPF.AI Generated. May Contain Errors. Read More Receive INCPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InnoCare Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCPF Stock News HeadlinesInnoCare Pharma Sets Board Meeting to Approve Q3 2026 ResultsOctober 12, 2026 | tipranks.comChina's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billionSeptember 23, 2026 | reuters.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 16 at 1:00 AM | Banyan Hill Publishing (Ad)InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call TranscriptAugust 24, 2026 | seekingalpha.comInnoCare Pharma Sets Board Meeting to Approve 2026 Interim ResultsAugust 11, 2026 | tipranks.comChina's Innocare's psoriasis drug meets main goal in late-stage trialJuly 27, 2026 | reuters.comInnoCare Shareholders Approve All Resolutions at 2026 AGMJune 16, 2026 | tipranks.comPhase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULARJune 4, 2026 | globenewswire.comSee More Headlines INCPF Stock Analysis - Frequently Asked Questions How have INCPF shares performed this year? InnoCare Pharma's stock was trading at $2.05 at the start of the year. Since then, INCPF stock has decreased by 22.0% and is now trading at $1.60. How do I buy shares of InnoCare Pharma? Shares of INCPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/16/2026Next Earnings (Estimated)10/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:INCPF CIKN/A Webwww.innocarepharma.com Phone861066609999FaxN/AEmployees1,259Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:INCPF) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InnoCare Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share InnoCare Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
